# A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus

> **NCT04767321** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pharma Holdings AS** · enrollment: 15 (actual)

## Conditions studied

- Nasal Decolonization of Staphylococcus Aureus

## Interventions

- **DRUG:** LTX-109 gel, 3% w/w
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04767321
- **Lead sponsor:** Pharma Holdings AS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-22
- **Primary completion:** 2021-03-23
- **Final completion:** 2021-06-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04767321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04767321, "A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04767321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*